Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
The ImplantCenter has recently opened the brand-new operating room suited for more complex treatments. This comes alongside numerous additions such as the launch of the four cosy apartments to rest after treatments at the clinic and an implant education facility to expand their services further. These expansions are part of constant improvements that have been occurring for the last 15 years, alongside high quality service.
The area of the clinic has increased by ten-fold to approximately 1800 m2 during the years. Moreover, the oral surgery division was opened in 2015, so eight dental treatment rooms and four oral surgery rooms are now in place today. All of the surgery rooms can serve ambulatory oral surgery treatments. The ImplantCenter is unique in Hungarian private dentistry because they can implement more complex treatments in the framework of one-day oral surgery procedure. This is due to the big and fully equipped operating room opened in November 2017. As part of the service, the ImplantCenter offers one and two-bed private rooms with medical supervision to their patients after each surgery.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8274651-implantcenter-hungarian-dental-service/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
Seqirus is now shipping its complete portfolio of seasonal influenza vaccines to customers in the US market for the 2016-2017 season. Seqirus is the only influenza vaccine manufacturer to produce influenza vaccines using both egg-based and cell culture technologies, and the only provider in the US that offers both quadrivalent and trivalent influenza vaccines, as well as the only adjuvanted seasonal influenza vaccine.
Seqirus is now shipping to the US all influenza vaccines in its portfolio, including Fluad™ (Influenza Vaccine, Adjuvanted), Flucelvax Quadrivalent™ (Influenza Vaccine), Afluria® (Influenza Vaccine), and Fluvirin® (Influenza Virus Vaccine) in advance of the peak of influenza season.
“Seqirus is proud to be a major contributor to the prevention and control of influenza by offering healthcare providers and pharmacists with a range of clinically proven, innovative vaccination options that help protect people against the debilitating effects of the disease,” said Brent MacGregor, Senior Vice President, Commercial Operations. “We are committed to being an early and reliable supplier of our influenza vaccines to help ensure that appropriate patients have plenty of time to get their annual immunization.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7902351-seqirus-franchise-shipment/
Having lost his mother to the disease, singer, songwriter Gavin DeGraw knows firsthand how devastating pancreatic cancer is for patients and their families. Gavin is turning his grief into action by helping the Lustgarten Foundation raise awareness by encouraging people to get involved with the Foundation.
“My mother didn’t make it and unfortunately right now that’s a common story. But it doesn’t have to be the story permanently,” DeGraw said. “By funding research, the Lustgarten Foundation is going to change the course of this disease. I encourage everyone to get involved in some way – join a walk or make a donation.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213753-lustgarten-foundation-pancreatic-cancer-awareness/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today congratulated trusted Edwards partner Dr. Albert Starr on receiving the 2015 Institut de France’s Grand Prix Scientifique in a Paris awards ceremony.
The Grand Prix is one of the largest prizes for scientific accomplishment and is considered the world’s most prestigious prize for cardiovascular research. The Institut’s board awarded Starr the Grand Prix in recognition of research that led to the world’s first successful artificial mitral valve implant in 1960. In the last 55 years, millions of patients around the world have benefitted from the emergence of the field of heart valve replacement and the many technological advances that followed.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7536851-france-grand-prix-starr-edwards/
High-powered research teams supported by the Crohn's & Colitis Foundation of America (CCFA) are gearing up for an ambitious new goal: developing individualized treatment approaches for patients with Crohn's disease and ulcerative colitis (UC), also known as inflammatory bowel diseases (IBD), through their Genetics and Microbiome Research Initiatives.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65964-ccfa-genetic-microbiome-discoveries-ibd-crohn-s-disease-ulcerative-colitis
Many people equate a conversation about hospice as being told they must give up. However, more than 1 million people across the nation have learned just the opposite. They’ve been touched by the National Hospice and Palliative Care Organization’s “Moments of Life: Made Possible by Hospice” campaign since its launch on May 15, 2014. The campaign’s intent is to debunk this myth, and show that hospice focuses on compassionate, person-centered care, which enables special moments and memories at the end of life for patients and loved ones.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7154752-national-hospice-and-palliative-care-organization-nhpco-moments-of-life-psa/
In this video, we'll teach you how to optimize your SEO.
If you're a doctor looking to improve your website traffic and rank in search, this video is for you! By following the tips in this video, you'll be able to improve your website's visibility and reach new patients who need your help!
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
The Celiac Disease Center at Columbia University, the premier center for celiac disease research and treatment, unveiled the I Didn’t Know video campaign, offering an inside look at the serious impact of celiac disease on patients at the 13th Anniversary gala on November 13th in New York City. The series chronicles the lives of several patients experiencing a wide range of debilitating symptoms associated with undiagnosed celiac disease, including an inability to walk, developmental delays, multiple miscarriages and infertility.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7322351-celiac-disease-center-at-columbia-university-public-service-announcements-and-gala/
